Cancer Therapeutics & Host Response Program Co-Leaders

Christian Jobin

Christian Jobin Ph.D.

Professor Of Medicine; Principal Investigator
Department: MD-GASTROENTEROLOGY
Mailing Address:
CGRC-461
CGRC-461
2033 MOWRY RD
GAINESVILLE FL 326100001
Physical Address:
2033 MOWRY RD
GAINESVILLE FL 32611
Accomplishments:
  • Associate Editor
    2017-2020 · Microbiome
  • Chair study section for Program Project Grant exploring the metabolic, epigenetic and microbiome drivers of inflammation driven malignancy
    2017 · Terry Fox Research Institute
  • Permanent Member
    2015-2020 · NIH GMPB
  • UF Senior Faculty Excellence in Research Award
    2015 · University of Florida
  • Study Section Memberships – Advisory Board
    2014-2016 · CIHR Institute Advisory Board of Infection and Immunity
  • Study Section Memberships – Advisory Board
    2014-2015 · AICR
  • Study Section Memberships -Advisory Board
    2014-2015 · American Society for Cancer
  • Study Section Memberships – Advisory Board
    2013-2020 · NIH NCI Chair ZRG1 DKUS-D: Role of the Microflora in the Etiology of Gastrointestinal Cancer
  • Study Section Memberships – Advisory Board
    2011-2020 · Ad Hoc NIH Gastrointestinal Mucosal Pathobiology (GMBP)
  • Study Section Memberships – Advisory Board
    2010-2013 · Canadian Institutes of Health Research, Vanier Canada Graduate Scholarships
  • Admission Committee
    2009-2012 · UNC Biological and Biomedical Sciences Program
  • IBD: Associate Editor
    2008-2016 · Cell Biology/Biochemistry/Molecular Biology
  • Study Section Memberships – Advisory Board
    2008-2011 · CCFA Study section (Fellowship and Career Awards)
  • Study Section
    2007-2020 · NIH Tumor Microenvironment (TME)
  • IBD: Section Editor
    2007-2008 · Cell Biology/Biochemistry/Molecular Biology
  • Editorial Board Member
    2005-2010 · Gastroenterology
  • Junior Faculty Development Award
    2005 · UNC
  • Fireman Young Scientist Basic Research Award
    2005 · American Gastroenterological Association
  • University Research Council Award
    2004 · Mucosal Immunology Society
  • Study Section Memberships – Advisory Board
    2003-2007 · Canadian Institutes of Health Research,  Experimental Medicine
  • Study Section Memberships – Advisory Board
    2002-2020 · Ad Hoc NIH Special Emphasis Panel NIDDK
  • Editorial Board Member
    2001-2009 · American Journal of Physiology
  • Anne Ferguson Award
    1999 · Mucosal Immunology Society
  • Young investigator travel award
    1999 · Mucosal Immunology
  • Career Development Award
    1998-1999 · CCFA
  • CCFA Young IBD Investigator Award
    1998 · “Regulation and modulation of the IkB/NF-kB transcriptional system in intestinal epithelial cells”
  • University Research Council Award
    1998 · University Research Council Award
  • CCFA young investigator travel award
    1996 · “Immune/non-immune cell interaction in intestinal inflammation” meeting in Florida
  • CCFA young investigator travel award
    1995 · “Interactions between genetics and microbiology in inflammatory bowel disease” meeting in South Carolina
  • Ph.D fellowships
    1991-1993 · Laval University
  • Ph.D fellowship
    1990-1991 · Hôpital Saint-François d’Assise
Publications:
Grants:
  • Jul 2022 ACTIVE
    Microbiota-mediated enhancement of the anti-tumor effect of natural killer cells
    NATL INST OF HLTH NCI · Principal Investigator
  • May 2022 ACTIVE
    Bacteriophage-mediated microbiota modification to prevent colorectal cancer development
    NATL INST OF HLTH NCI · Principal Investigator
  • Dec 2021 ACTIVE
    Bacteriophages as Modulators of Bacterial Colonization
    NATL INST OF HLTH NIAID · Other
  • Aug 2021 ACTIVE
    Role of RORgt+ (note: g: is gamma symbol) lymphocytes in Gut Tissue Homeostasis
    NATL INST OF HLTH NIAID · Co-Investigator
  • Jul 2021 ACTIVE
    Exploiting microbiota metabolism for colorectal cancer prevention
    YALE UNIV · Principal Investigator
  • Jun 2021 ACTIVE
    Modulation of microbiome function by host-derived noncoding small RNA
    NATL INST OF HLTH NIAID · Principal Investigator
  • Mar 2019 – Nov 2022
    Role of the microbiota in DNA methylation and CRC development
    CORIELL INSTITUTE FOR MEDICAL RESEARCH · Principal Investigator
  • Jan 2019 ACTIVE
    Human milk metabolomics and microbe-host interactions associated with pediatric obesity
    NATL INST OF HLTH NIDDK · Other
  • Jul 2018 ACTIVE
    Role of Bacteria in Colitis-Associated Colon Cancer
    NATL INST OF HLTH NIDDK · Principal Investigator
  • Jan 2018 ACTIVE
    The role of the microbiome on pancreatic carcinogenesis in a murine model
    AMER CANCER SOC · Other
  • Dec 2017 – Feb 2019
    Role of the microbiota in DNA methylation and CRC development
    TEMPLE UNIVERSITY · Principal Investigator
  • Dec 2017 – Nov 2022
    Chemical approaches toward the identification, functional analysis, and biosynthesis of small molecule cyclomodulin
    YALE UNIV · Principal Investigator
  • Oct 2016 – Sep 2018
    Role of Gram negative bacterial lipopolysaccharide in CXCR4-mediated pancreatic carcinogenesis
    ASSOC OF VA SURGEONS FOU · Faculty
  • Aug 2016 – Dec 2021
    ACE2, Brain, Gut Dysbiosis in Pulmonary Hypertension
    NATL INST OF HLTH NHLBI · Co-Investigator
  • Jul 2016 – Jun 2019
    Impact of host signaling on microbial activities in the development of colitis-associated colorectal cancer
    CROHNS & COLITIS FOUNDATION · Other
  • Apr 2016 – Sep 2021
    Brain-Gut Microbiome-Immune Axis in Hypertension
    NATL INST OF HLTH NHLBI · Project Manager
  • Dec 2015 – Nov 2019
    Mechanism by which H2S-producing bacteria influence development of colorectal cancer
    NATL INST OF HLTH NCI · Principal Investigator
  • Jul 2015 ACTIVE
    Florida Academic Cancer Center Alliance Seed Grants
    UF HEALTH SHANDS HOSPITAL · Project Manager
  • Jun 2015 – Nov 2017
    Microbial Factors Implicated in the Development of Colorectal Cancer
    UF DSR OPPORTUNITY FUND · Principal Investigator
  • Feb 2015 ACTIVE
    UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
    UF HEALTH SHANDS HOSPITAL · Project Manager
  • Jan 2015 – Dec 2021
    Impact of microbiota-mediated biotransformation of black tea polyphenols on GI health
    NATL CTR FOR COMPLEM AND INTEGRATIVE HLT · Principal Investigator
  • May 2014 – May 2019
    Multiple Sponsors
    MULTIPLE SPONSORS · Principal Investigator
  • Jul 2013 – Jun 2021
    Florida Center for Brain Tumor Research – Statewide Brain Tumor Registry Program at the McKnight Brain Institute
    FL DEPT OF HLTH · Project Manager
  • Jul 2013 – Mar 2018
    Role of Bacteria in Colitis-Associated Colon Cancer
    NATL INST OF HLTH NIDDK · Principal Investigator
  • Jul 2013 – Jun 2016
    Regulation of Immunosuppressive Molecules in IBD
    NATL INST OF HLTH NIDDK · Principal Investigator
Patents:
  • Published August 2020
    Perfusion Enabled Bioreactors
    #US-2020-0354668-A1
Elias Sayour

Elias Sayour MD, PhD

Assistant Professor
Department: Department of Neuroscience
Mailing Address:
PO BOX 100265
PO BOX 100265
DEPARTMENT OF NEUROSURGERY
GAINESVILLE FL 326100265
Physical Address:
L2-100
1149 Newell Dr.
GAINESVILLE FL 32611

Elias Sayour, MD, PhD, is an assistant professor in the UF departments of neurosurgery and pediatrics at the University of Florida. He is also a principal investigator of the ribonucleic acid engineering laboratory at the Preston A. Wells, Jr. Center for Brain Tumor Therapy. He received his bachelor’s degree from Fordham University, his medical degree from the University of Buffalo and his doctorate from Duke University.

He completed his residency in pediatrics at Cohen’s Children’s Medical Center in New York and his fellowship at Duke University Medical Center. During his fellowship training, he completed a two-year National Institutes of Health research fellowship in cancer biology and developmental therapeutics. His primary research focus is developing tumor RNA loaded nanocarriers to re-direct host immunity against pediatric brain tumors.

Dr. Sayour is an NIH-funded investigator focused on on developing new nanotech vaccines to reprogram the immune system against cancer cells. He is investigating the use of personalized nanoparticles small enough to deliver essential information to the immune system educating it reject pediatric cancer. Currently his group is investigating the safety and efficacy of this novel vaccine formulation in canines with malignant brain tumors before translation into dedicated human studies.

Dr. Sayour’s work has been nationally recognized by the American Society of Pediatric Hematology-Oncology, National Institutes of Health, and U.S. Department of Defense. He has been the recipient of the Hyundai Hope on Wheels Hope Award, St. Baldrick’s Scholar Award, and the American Brain Tumor Association Discovery Award.

Dr. Sayour is board-certified in general pediatrics and pediatric hematology-oncology.

He has presented his work at several national meetings and is a member of the Children’s Oncology Group, Society of Neuro-Oncology and the American Society of Pediatric Hematology-Oncology.

Certifications:
  • Pediatrics
    American Board of Pediatrics
Specialties:
  • Neurosurgery
  • Pediatrics
Subspecialties:
  • Pediatric Hematology-Oncology
Clinical Interests:
  • Brain tumor – children
Research Summary:
Research Interests:
  • Immunotherapeutics for CNS malignancies
  • Pediatric brain tumors
Publications:
Grants:
  • Dec 2022 ACTIVE
    Establishment of 3D metastatic osteosarcoma organoid model to accelerate combination immunotherapy
    HYUNDAI HOPE ON WHEELS · Other
  • Jul 2022 ACTIVE
    Leveraging RNA-lipid nanoparticle vaccines to induce immune response in metastatic pulmonary osteosarcoma
    THE V FOU FOR CANCER RESEARCH · Co-Investigator
  • Jul 2022 ACTIVE
    Using RNA-nanoparticle vaccines to overcome the immunosuppressive tumor microenvironment of canine osteosarcoma
    MIB AGENTS · Other
  • May 2022 ACTIVE
    Patterns of resistance to initial therapeutic treatment in Ewings Sarcoma
    Hematology/Oncology Pharmacy Asso Fou · Co-Investigator
  • Apr 2022 ACTIVE
    Unlocking CAR T cell efficacy against osteosarcoma using adjuvant RNA vaccine
    FL DEPT OF HLTH LIVE LIKE BELLA · Other
  • Feb 2022 ACTIVE
    A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Feb 2022 – Jun 2022
    A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Jan 2022 ACTIVE
    Development of RNA Loaded Nanoparticles for Children with Refractory Solid Tumors
    NATL PEDIATRIC CANCER FOU · Principal Investigator
  • Jan 2022 – Jun 2022
    Development of RNA Loaded Nanoparticles for Children with Refractory Solid Tumors
    H LEE MOFFITT CANCER CTR & RES INST · Principal Investigator
  • Oct 2021 ACTIVE
    Pan-Neoantigen Targeted RNA-nanoparticles for Recurrent Pulmonary Osteosarcoma
    CHANCE FOR LIFE FOUNDATION · Principal Investigator
  • Sep 2021 ACTIVE
    Immune correlate studies in pediatric high-grade glioma patients receiving RNA nanoparticle vaccines
    TEAM JACK FOUNDATION · Principal Investigator
  • Jul 2021 – Aug 2022
    Immunotherapeutic targeting of osteosarcoma with nanoparticle vaccines
    Rally Foundation · Principal Investigator
  • Jun 2021 ACTIVE
    Precision mEdicine and Adoptive Cellular tHerapy for the treatment of recurrent neuroblastoma and newly diagnosed diffuse intrinsic pontine glioma (DIPG)
    ATRIUM HEALTH · Principal Investigator
  • Apr 2021 ACTIVE
    Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis
    NATL INST OF HLTH NCI · Co-Investigator
  • Feb 2021 ACTIVE
    Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
    NATL INST OF HLTH NCI · Principal Investigator
  • Jan 2021 ACTIVE
    A Randomized, Double-Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Jul 2020 ACTIVE
    Pediatric Brain Tumor ConsortiumA multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumors
    ST JUDE CHILDRENS RESEARCH HOSPITAL · Principal Investigator
  • Jul 2020 ACTIVE
    RNA-nanoparticle vaccines for pediatric high-grade glioma
    CURESEARCH FOR CHILDRENS CANCER · Principal Investigator
  • Jul 2020 – Jun 2022
    Translating Personalized RNA Nanoparticle Vaccines for Oral Cancer
    OCALA ROYAL DAMES FOR CANCER RESEARCH · Principal Investigator
  • Jul 2020 – Jul 2021
    Remodeling Host Immunity in Oral Cancer with Personalized RNA Nanoparticle Vaccines
    NATL INST OF HLTH NIDCR · Other
  • Jun 2020 ACTIVE
    Novel immunologic therapy of soft tissue sarcoma
    FL DEPT OF HLTH LIVE LIKE BELLA · Co-Investigator
  • Jun 2020 ACTIVE
    Lipidnanoparticle vaccines targeting metastatic lung cancer from osteosarcoma
    FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE · Principal Investigator
  • Jun 2020 ACTIVE
    Multi-center phase I study evaluating lipid-nanoparticle vaccines against pediatric high-grade glioma
    FL DEPT OF HLTH LIVE LIKE BELLA · Principal Investigator
  • May 2020 – Jan 2022
    A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Dec 2019 – Jun 2022
    Nanoparticles targeting genetic translocations in pediatric brain tumors
    HYUNDAI HOPE ON WHEELS · Principal Investigator
  • Sep 2019 ACTIVE
    A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
    ICON CLINICAL RESEARCH INC · Principal Investigator
  • Aug 2019 – Sep 2022
    A Target Validation Study of Fimepinostat in Children and Young Adults with Newly Diagnosed Diffuse Intristic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Jul 2019 – Dec 2020
    Re-programming immunity to target mutations across medulloblastoma subtypes
    ST BALDRICKS FOUNDATION · Principal Investigator
  • Jul 2019 – Sep 2021
    Immunotherapeutic targeting of osteosarcoma with nanoparticle vaccines
    Rally Foundation · Principal Investigator
  • Jan 2019 ACTIVE
    Development of personalized RNA loaded nano particles for children with refractory solid tumors.
    UF FOUNDATION · Principal Investigator
  • Dec 2018 – Mar 2022
    A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children and Young Adults with High Grade Glioma (Excluding Diffuse Intrinsic Pontine Glioma)
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Jul 2018 ACTIVE
    Florida Center for Brain Tumor Research
    FL DEPT OF HLTH · Project Manager
  • Jul 2018 – Dec 2021
    Legacy Foundation
    UF FOUNDATION · Project Manager
  • Jul 2018 – Jun 2020
    Host Immunomodulatory RNA-nanoparticles targeting malignant canine glioma
    UF FOUNDATION · Principal Investigator
  • Mar 2018 – Nov 2022
    Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E – or BRAF Ins T mutant Brain Tumors
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Jan 2018 – Jun 2020
    Development of Personalized RNA Loaded Nanoparticles for Children with Refractory Solid Tumors
    H LEE MOFFITT CANCER CTR & RES INST · Principal Investigator
  • Dec 2017 ACTIVE
    Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
    UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
  • Nov 2017 ACTIVE
    Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas (Phase I)
    H LEE MOFFITT CANCER CTR & RES INST · Principal Investigator
  • Sep 2017 – Sep 2020
    RNA-nanoparticles targeting H3.3 K27M epitopes in diffuse intrinsic pontine glioma
    US ARMY MED RES ACQUISITION · Principal Investigator
  • Sep 2017 – Jun 2021
    UFHCC Triple Negative Breast Cancer (TNBC) Pilot Project Program
    MULTIPLE SPONSORS · Project Manager
  • Jul 2017 – Dec 2019
    Immunotherapeutic targeting of osteosarcoma neoantigens
    Rally Foundation · Principal Investigator
  • May 2017 ACTIVE
    Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies
    BRISTOL MYERS SQUIBB CO · Principal Investigator
  • Apr 2017 – Jun 2021
    OoR CTSI Institutional Matching Support
    UF DIV OF SPONSORED RES MATCHING FUNDS · Project Manager
  • Nov 2016 ACTIVE
    Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Primitive Neuro-Ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single-Cycle (Low Risk Patients) or Randomization (High Risk Patients) to either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue
    NATIONWIDE CHILDRENS HOSPITAL · Principal Investigator
  • Sep 2016 – Sep 2021
    A Clinical and Molecular Risk-directed Therapy for Newly Diagnosed Medulloblastoma
    ST JUDE CHILDRENS RESEARCH HOSPITAL · Principal Investigator
  • Sep 2016 – Aug 2021
    Harnessing the Immunologic Capacity of RNA-nanoparticle Vaccines Targeting Glioblastoma
    NATL INST OF HLTH NCI · Principal Investigator
  • Jul 2016 – Jun 2020
    Re-programming immunity to target mutations across medulloblastoma subtypes
    ST BALDRICKS FOUNDATION · Principal Investigator
  • Jul 2016 – Jun 2020
    RNA nanoparticle vaccines targeting malignant canine gliomas
    OCALA ROYAL DAMES FOR CANCER RESEARCH · Principal Investigator
  • Apr 2016 – Mar 2018
    Re-programming osteosarcoma immune evasion with CAR modified T cells
    UF FOUNDATION · Principal Investigator
  • Jul 2015 ACTIVE
    Florida Academic Cancer Center Alliance Seed Grants
    UF HEALTH SHANDS HOSPITAL · Project Manager
  • Dec 2014 – Jun 2017
    Efficacious, Translational and Personalized RNA-nanoparticle Vaccines Targeting Pediatric Brain Tumors
    HYUNDAI HOPE ON WHEELS · Principal Investigator
  • Jul 2013 – Jun 2021
    Florida Center for Brain Tumor Research – Statewide Brain Tumor Registry Program at the McKnight Brain Institute
    FL DEPT OF HLTH · Project Manager
Patents:
  • Published October 2021
    Compositions for Treatment of Diffuse Intrinsic Pontine Glioma
    #US-2022-0218808-A1
  • Published February 2021
    Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
    #US-2021-0170005-A1
  • Published November 2020
    Magnetic Liposomes and Related Treatment and Imaging Methods
    #US-2021-0077399-A1
  • Published February 2020
    A Monophosphoryl Lipid A Liposome Based Cancer Vaccine
    #US-2022-0133872-A1
Education:
  • 2013
    Fellowship – Pediatric Hematology/Oncology
    Duke University
  • 2010
    Residency – Pediatrics
    Long Island Jewish Medical Center
  • 2007
    Medical Degree
    University at Buffalo